Neurogene Inc. Investing Cash Flow
Neurogene Inc. (NGNE) reported Investing Cash Flow of $52.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Neurogene Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $6.10M, a 18.07% decline year-over-year.
- Neurogene Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $46.24M.
- Neurogene Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $29.61M.
- Neurogene Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $21.99M.
- Neurogene Inc. net cash provided by (used in) investing activities for fiscal 2025 was $14.00M.
- Neurogene Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$125.26M, a 588.59% decline from fiscal 2023.
- Neurogene Inc. net cash provided by (used in) investing activities for fiscal 2023 was $25.64M.
- Neurogene Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$2.23M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $52.34M 10-Q · filed 2026-08-11 | $81.95M derived: sum of 3 quarters · filed 2026-08-11 | $103.94M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $46.24M 10-Q · filed 2026-05-12 | $75.85M derived: sum of 2 quarters · filed 2026-05-12 | $97.84M derived: sum of 3 quarters · filed 2026-05-12 | $105.29M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $29.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $51.60M derived: sum of 2 quarters · filed 2026-03-24 | $59.05M derived: sum of 3 quarters · filed 2026-08-11 | $14.00M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $21.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $29.44M derived: sum of 2 quarters · filed 2026-08-11 | -$15.61M 10-Q · filed 2025-11-13 | -$118.22M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $7.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$37.59M 10-Q · filed 2026-08-11 | -$140.21M derived: sum of 3 quarters · filed 2026-08-11 | -$169.18M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$45.05M 10-Q · filed 2026-05-12 | -$147.66M derived: sum of 2 quarters · filed 2026-05-12 | -$176.63M derived: sum of 3 quarters · filed 2026-05-12 | -$200.24M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$102.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$131.58M derived: sum of 2 quarters · filed 2026-03-24 | -$155.20M derived: sum of 3 quarters · filed 2026-03-24 | -$125.26M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$28.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$52.58M derived: sum of 2 quarters · filed 2025-11-13 | -$22.64M 10-Q · filed 2025-11-13 | $3.19M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$23.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $6.32M 10-Q · filed 2025-08-11 | $32.15M derived: sum of 3 quarters · filed 2025-08-11 | $32.07M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $29.93M 10-Q · filed 2025-05-09 | $55.77M derived: sum of 2 quarters · filed 2025-05-09 | $55.68M derived: sum of 3 quarters · filed 2025-05-09 | $55.60M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | $25.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $25.75M derived: sum of 2 quarters · filed 2025-03-24 | $25.67M derived: sum of 3 quarters · filed 2025-03-24 | $25.64M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | -$82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | -$164.00K derived: sum of 2 quarters · filed 2024-11-18 | -$193.00K 10-Q · filed 2024-11-18 | $8.68M 10-Q · filed 2023-11-14 | $65.18M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2023-06-30 | -$82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$111.00K 10-Q · filed 2024-08-09 | $10.29M 10-Q · filed 2023-08-10 | $65.26M derived: sum of 3 quarters · filed 2024-08-09 | $37.41M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | -$29.00K 10-Q · filed 2024-05-10 | $10.71M 10-Q · filed 2023-05-08 | $65.34M derived: sum of 2 quarters · filed 2024-05-10 | $37.49M derived: sum of 3 quarters · filed 2024-05-10 | -$1.81M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $65.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $37.52M derived: sum of 2 quarters · filed 2024-03-18 | -$1.78M derived: sum of 3 quarters · filed 2024-03-18 | -$2.23M 10-K · filed 2024-03-18 | -$59.13M 10-K · filed 2023-03-20 | |||
| 2022-09-30 | -$27.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$67.15M derived: sum of 2 quarters · filed 2023-11-14 | -$67.60M 10-Q · filed 2023-11-14 | -$68.00M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$39.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$39.75M 10-Q · filed 2023-08-10 | -$40.15M derived: sum of 3 quarters · filed 2023-08-10 | -$40.73M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$452.00K 10-Q · filed 2023-05-08 | -$848.00K derived: sum of 2 quarters · filed 2023-05-08 | -$1.44M derived: sum of 3 quarters · filed 2023-05-08 | -$2.63M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | -$396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$983.00K derived: sum of 2 quarters · filed 2023-03-20 | -$2.17M derived: sum of 3 quarters · filed 2023-03-20 | -$3.26M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$587.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.78M derived: sum of 2 quarters · filed 2022-11-14 | -$2.87M 10-Q · filed 2022-11-14 | -$3.52M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$2.28M 10-Q · filed 2022-08-09 | -$2.93M derived: sum of 3 quarters · filed 2022-08-09 | -$3.42M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$1.09M 10-Q · filed 2022-05-09 | -$1.74M derived: sum of 2 quarters · filed 2022-05-09 | -$2.23M derived: sum of 3 quarters · filed 2022-05-09 | -$3.20M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | -$653.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$1.14M derived: sum of 2 quarters · filed 2022-03-01 | -$2.11M derived: sum of 3 quarters · filed 2022-03-01 | -$2.22M 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | -$487.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$1.46M derived: sum of 2 quarters · filed 2021-11-04 | -$1.57M 10-Q · filed 2021-11-04 | -$2.35M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$972.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.08M 10-Q · filed 2021-08-05 | -$1.86M derived: sum of 3 quarters · filed 2021-08-05 | |||||
| 2020-03-31 | -$107.00K 10-Q · filed 2021-05-12 | -$889.00K derived: sum of 2 quarters · filed 2021-05-12 | ||||||
| 2019-12-31 | -$782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$688.00K 10-K · filed 2021-03-25 | ||||||
| 2019-09-30 | $94.00K 10-Q · filed 2020-11-09 | |||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $3.02M derived: sum of 2 quarters · filed 2020-03-12 | $25.99M derived: sum of 3 quarters · filed 2020-03-12 | $55.95M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $25.99M derived: sum of 2 quarters · filed 2019-11-13 | $55.95M 10-Q · filed 2019-11-13 | $72.44M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $22.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $52.93M 10-Q · filed 2019-08-01 | $69.42M derived: sum of 3 quarters · filed 2020-03-12 | $100.89M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $29.96M 10-Q · filed 2019-05-07 | $46.44M derived: sum of 2 quarters · filed 2020-03-12 | $77.92M derived: sum of 3 quarters · filed 2020-03-12 | $94.08M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $47.96M derived: sum of 2 quarters · filed 2020-03-12 | $64.12M derived: sum of 3 quarters · filed 2020-03-12 | $64.01M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | $31.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $47.63M derived: sum of 2 quarters · filed 2018-11-07 | $47.53M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $16.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $16.05M 10-Q · filed 2018-08-08 | ||||||
| 2017-03-31 | -$108.00K 10-Q · filed 2018-05-08 | |||||||
| 2016-12-31 | -$48.06M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |